Quest for the right Drug

|
עמוד הבית / מינוקסי 5 / מידע מעלון לרופא

מינוקסי 5 MINOXI 5 (MINOXIDIL)

תרופה במרשם תרופה בסל נרקוטיקה ציטוטוקסיקה

צורת מתן:

קרקפת - חיצוני : TOPICAL- SCALP

צורת מינון:

תמיסה : SOLUTION

Special Warning : אזהרת שימוש

4.4   Special warnings and precautions for use
Before using Minoxi 5, the user should determine that the scalp is normal and healthy. Topical minoxidil should not be applied to inflamed, infected, irritated or painful scalp skin (see section 4.3).

Topical minoxidil is only indicated for the treatment of alopecia androgenetica and should not be used in other types of hair loss for example when there is no family history of hair loss, hair loss is sudden and/or patchy, hair loss is due to childbirth or the reason for hair loss is unknown.

The patient should stop using Minoxi 5 and see a doctor if hypotension is detected or if the patient is experiencing chest pain, rapid heart beat, faintness or dizziness, sudden unexplained weight gain, swollen hands or feet or persistent redness or irritation of the scalp or other unexpected new symptoms occur (see section 4.8).

Patients with known cardiovascular disease or cardiac arrhythmia should contact a physician before using Minoxi 5.

Some patients have experienced changes in hair colour and/or texture with use of minoxidil.
Minoxi 5 is for external use only. Do not apply to areas of the body other than the scalp.

Using more than the recommended dose or more often will not improve results.

Unwanted hair growth may be caused by the transfer of the product to areas other than the scalp.

Hands should be washed thoroughly after applying the solution. Inhalation of the spray mist should be avoided.

Some consumers reported increased hair shedding upon initiation of therapy with minoxidil. This is most likely due to minoxidil’s action of shifting hairs from the resting telogen phase to the growing anagen phase (old hairs fall out as new hairs grow in their place). This temporary increase in hair shedding generally occurs two to six weeks after beginning treatment and subsides within a couple of weeks. If shedding persists (> 2 weeks), users should stop using Minoxi 5 and consult their doctor.
Users should be aware that, whilst extensive use of minoxidil has not revealed evidence that sufficient minoxidil is absorbed to have systemic effects, greater absorption because of misuse, individual variability, unusual sensitivity or decreased integrity of the epidermal barrier caused by inflammation or disease processes in the skin (e.g. excoriations of the scalp, or scalp psoriasis) could lead, at least theoretically, to systemic effects.

Accidental ingestion may cause serious cardiac adverse events. Therefore, this product has to be kept out of the reach of children.

This medicine contains 244 mg of alcohol (ethanol) in each 1 ml. It may cause burning sensation on damaged skin. Ethanol may cause burning and irritation of the eye. In the event of accidental contact with sensitive surfaces (eye, abraded skin and mucous membranes) the area should be bathed with large amounts of cool tap water.

This medicine contains 514 mg of propylene glycol in each 1 ml. Propylene glycol may cause skin irritation. Because this medicine contains propylene glycol, do not use it on open wounds or large areas of broken or damaged skin (such as burns) without checking with your doctor or pharmacist.
Patients should be advised to consult their doctor or pharmacist if they are concerned at any time during treatment with Minoxi 5.

Effects on Driving

4.7   Effects on ability to drive and use machines
This product may cause dizziness or hypotension (see section 4.8). If affected, patients should not drive or operate machinery.
שימוש לפי פנקס קופ''ח כללית 1994 לא צוין
תאריך הכללה מקורי בסל לא צוין
הגבלות לא צוין

רישום

109 97 29349 00

מחיר

0 ₪

מידע נוסף

עלון מידע לרופא

08.06.23 - עלון לרופא

עלון מידע לצרכן

02.04.19 - עלון לצרכן אנגלית 02.04.19 - עלון לצרכן עברית 02.04.19 - עלון לצרכן ערבית 08.06.23 - עלון לצרכן אנגלית 08.06.23 - עלון לצרכן עברית 08.06.23 - עלון לצרכן ערבית 24.06.13 - החמרה לעלון

לתרופה במאגר משרד הבריאות

מינוקסי 5

קישורים נוספים

RxList WebMD Drugs.com